{"id":97961,"date":"2026-07-06T07:01:14","date_gmt":"2026-07-06T07:01:14","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/97961\/"},"modified":"2026-07-06T07:01:14","modified_gmt":"2026-07-06T07:01:14","slug":"novartis-to-acquire-uk-based-myricx-bio-for-up-to-1-5-billion-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/97961\/","title":{"rendered":"Novartis to acquire UK-based Myricx Bio for up to $1.5 billion"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">ZURICH, July 6 (Reuters) &#8211; Swiss drugmaker Novartis said on Monday \u200cit had agreed to pay \u200cup to $1.5 billion for U.K.-based biotechnology firm \u200bMyricx Bio in a deal expected to close in the second half of 2026.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">In a statement, Novartis \u200csaid it \u2060would pay $1.1 billion upfront, alongside up to $400 million in \u2060potential milestone payments, to acquire London-based Myricx Bio, which develops \u200bantibody-drug conjugates \u200bused for \u200btreating cancer.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;ADCs have \u200cbecome an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand \u200ctheir impact for patients,&#8221; \u200bsaid Fiona Marshall, \u200bpresident of \u200bbiomedical research at Novartis.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;This \u200cproposed acquisition reflects our \u200bstrategy \u200bto scale innovative platforms, as we have with radioligand therapies, to \u200bdeliver \u200cmore durable, transformative treatments for \u200bpatients.&#8221;  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">(Writing by Dave Graham, Editing \u200bby Miranda Murray)  <\/p>\n","protected":false},"excerpt":{"rendered":"ZURICH, July 6 (Reuters) &#8211; Swiss drugmaker Novartis said on Monday \u200cit had agreed to pay \u200cup to&hellip;\n","protected":false},"author":2,"featured_media":97962,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[23302,48615,206,48616],"class_list":["post-97961","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-fiona-marshall","tag-myricx-bio","tag-novartis","tag-treating-cancer"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116871750659268010","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/97961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=97961"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/97961\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/97962"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=97961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=97961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=97961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}